2025
Drip and ship in patients with acute ischemic stroke: a narrative review
PALAIODIMOU, Lina; Nikolaos M PAPAGEORGIOU; Eleni BAKOLA; Aikaterini THEODOROU; Michele ROMOLI et al.Základní údaje
Originální název
Drip and ship in patients with acute ischemic stroke: a narrative review
Autoři
PALAIODIMOU, Lina; Nikolaos M PAPAGEORGIOU; Eleni BAKOLA; Aikaterini THEODOROU; Michele ROMOLI; Amrou SARRAJ; Robert MIKULÍK; Nitin GOYAL; Diana Aguiar de SOUSA; Theodoros KARAPANAYIOTIDES; Ioanna KOUTROULOU; Pierre SENERS; Mira KATAN; Simona SACCO; Guillaume TURC a Georgios TSIVGOULIS
Vydání
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, LONDON, SAGE PUBLICATIONS LTD, 2025, 1756-2856
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30210 Clinical neurology
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 4.100 v roce 2024
Označené pro přenos do RIV
Ano
Organizační jednotka
Lékařská fakulta
UT WoS
EID Scopus
Klíčová slova anglicky
acute ischemic stroke; comprehensive stroke center; drip and ship; endovascular treatment; intravenous thrombolysis; mothership; primary stroke center; service organization
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 23. 1. 2026 10:26, Mgr. Tereza Miškechová
Anotace
V originále
Acute ischemic stroke (AIS) is a leading cause of long-term disability and mortality worldwide, necessitating the rapid implementation of time-sensitive reperfusion therapies to improve outcomes. The "drip and ship" (DS) model, in which intravenous thrombolysis (IVT) is initiated at a primary stroke center (PSC) followed by transfer for endovascular thrombectomy (EVT) at a comprehensive stroke center, is widely adopted, particularly in regions with limited immediate EVT access. This narrative review synthesizes evidence from randomized-controlled clinical trials, large-scale observational registries, meta-analyses, and expert-consensus statements to comprehensively analyze the DS model in AIS management, compare it with the mothership (MS) paradigm, and evaluate current evidence regarding workflow optimization, pharmacologic strategies, and system-level innovations. Evidence comparing DS and MS models highlights the complexity of balancing early IVT with minimizing delays to EVT, with regional factors influencing the optimal approach. Reducing door-in-door-out times is critical within DS pathways, as prolonged interhospital transfer is associated with worse outcomes, emphasizing the need for streamlined protocols, prehospital notification, and telemedicine integration. Bridging therapy with IVT, particularly using tenecteplase, is associated with improved rates of early recanalization, supporting its continued use within DS workflows. Emerging adjunctive therapies offer potential for enhancing arterial recanalization and microcirculatory reperfusion without delaying transfer. The "drive-the-doctor" paradigm, involving the transfer of neurointerventionalists to PSCs, may further reduce onset-to-reperfusion times in geographically challenging settings. Mobile stroke units, equipped with CT imaging and telemedicine capabilities, represent an additional strategy to initiate IVT in the field while expediting triage decisions for EVT. Collectively, these advancements support the continued refinement of the DS model, emphasizing the need for structured system-level improvements to optimize timely reperfusion and functional recovery in AIS patients. Continued research is necessary to further define optimal strategies within the DS framework to ensure equitable and effective stroke care across diverse healthcare environments.